MedKoo Cat#: 465808 | Name: RMC-4630
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RMC-4630 is a SHP2 inhibitor. RMC-4630 shows reasonable tolerability and preliminary signs of clinical activity in patients with NSCLC harboring KRAS mutations.

Chemical Structure

RMC-4630
RMC-4630
CAS#2172652-48-9

Theoretical Analysis

MedKoo Cat#: 465808

Name: RMC-4630

CAS#: 2172652-48-9

Chemical Formula: C20H27ClN6O2S

Exact Mass: 450.1605

Molecular Weight: 450.99

Elemental Analysis: C, 53.27; H, 6.03; Cl, 7.86; N, 18.64; O, 7.10; S, 7.11

Price and Availability

Size Price Availability Quantity
5mg USD 700.00 2 Weeks
10mg USD 1,200.00 2 Weeks
25mg USD 2,250.00 2 Weeks
50mg USD 3,400.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RMC-4630; RMC4630; RMC 4630; SHP2-IN-7; SHP2IN7; SHP2 IN 7; Vociprotafib
IUPAC/Chemical Name
(6-((2-amino-3-chloropyridin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-methylpyrazin-2-yl)methanol
InChi Key
HISJAYUQVHMWTA-BLLLJJGKSA-N
InChi Code
InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1
SMILES Code
NC1=C(Cl)C(SC2=C(C)N=C(N3CCC4([C@H](N)[C@H](C)OC4)CC3)C(CO)=N2)=CC=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 450.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Ou, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., ... & Bivona, T. (2020). A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial. Journal of Thoracic Oncology, 15(2), S15-S16. Falchook, G., Li, B. T., Marrone, K. A., Bestvina, C. M., Langer, C. J., Krauss, J. C., ... & Hong, D. S. (2022). OA03. 03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p. G12C-mutated NSCLC and other solid tumors. Journal of Thoracic Oncology, 17(9), S8. Bendell, J., Ulahannan, S., Koczywas, M., Brahmer, J., Capasso, A., Eckhardt, S. G., ... & Ou, S. H. (2020). Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. European Journal of Cancer, 138, S8-S9.